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CASE REPORT Open Access
Spontaneous regression of a primary
squamous cell lung cancer following
biopsy: a case report
Nathan Esplin1* , Khadija Fergiani1, Timothy B. Legare1, John W. Stelzer1, Hammad Bhatti2 and Sayed K. Ali2
Abstract
Background: Spontaneous regression has been defined as occurring when the malignant tumor mass partially or
completely disappears without any treatment or as a result of a therapy considered inadequate to influence systemic
neoplastic disease. Recently, studies have implicated immunological responses as likely being involved. We report a
case of a patient with squamous cell carcinoma of the lung who experienced spontaneous regression following biopsy
without other intervention.
Case presentation: A 57-year-old white man was referred to our pulmonary clinic after an incidental finding of a
nodule in the lower lobe of his left lung. Thoracic computed tomography revealed a 2.0 × 1.4 × 1.5 cm spiculated
nodule in the superior segment of the left lower lobe. Workup identified the mass as a squamous cell carcinoma that
was clinically staged as T1M0N0. The patient deferred treatment of this lesion. He undertook no significant lifestyle or
medical changes. Three months later, computed tomography revealed that, compared with the initial study, the
solitary mass had decreased in size to 1.6 × 0.9 × 0.9 cm. Follow-up computed tomography 1 year after the original
workup demonstrated that the nodule had stabilized to its smaller size.
Conclusions: Studies have shown that immunological response can be initiated by trauma to an area. Because the
tumor regression became evident in our patient only after the tissue biopsy, his immune response to the
surgical procedure seems to be a plausible contributor to the spontaneous regression. Further understanding
of spontaneous regression can potentially impact the identification of neoplastic drug targets or even the course of a
patient’s treatment plan and goals.
Keywords: Spontaneous regression, Squamous cell carcinoma, Immune response
Background
Spontaneous regression (SR) of a tumor was originally
defined as occurring “when the malignant tumor mass
partially or completely disappears without any treatment
or as a result of a therapy considered inadequate to in-
fluence systemic neoplastic disease” [1, 2]. SR of primary
malignant lung tumors remains a rare occurrence [1, 3].
The precise mechanism behind SR is a focus of ongoing
research. Recent studies have revealed a possible influence
of various processes, including immune mediation, tumor
inhibition by cytokines or growth factors, hormonal influ-
ence, elimination of carcinogenesis, tumor necrosis,
angiogenesis inhibition, apoptosis, epigenetic mechanisms,
and induction of differentiation [2–5]. We present a case
of a patient with primary squamous cell lung cancer, stage
T1M0N0, that demonstrated SR following biopsy with no
additional therapeutic intervention by the medical team or
lifestyle change by the patient.
Case presentation
A 57-year-old white man was seen in the pulmonary
clinic of our institution after an abdominal/pelvic com-
puted tomographic (CT) scan for microscopic hematuria
incidentally demonstrated a nodule in the left lower lobe
(LLL) of his lung. The patient reported periodic chronic
cough but denied any hemoptysis or any other alarming
symptoms. His comorbidities consisted of hypertension,
hyperlipidemia, latent syphilis, obesity, and diabetes
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mellitus type 2 with peripheral neuropathy. His daily
medications included aspirin, lisinopril, hydrochlorothia-
zide, gemfibrozil, metformin, glipizide and amitriptyline.
He reported a greater than 40-year history of smoking an
average of two packs of cigarettes per day. He lived alone at
home and was able to perform all of his activities of daily
living. He reported that both his parents had died from
lung cancer due to tobacco use. His physical examination
and laboratory results had no pertinent abnormal findings.
A thoracic CT workup in April 2016 revealed a 2.0 ×
1.4 × 1.5 cm spiculated nodule in the superior segment
of the LLL (Fig. 1). This solitary nodule did not extend
into the pleural surface, and no regional lymph node en-
largement was noted. Bronchoscopy with alveolar lavage
revealed malignant cells. On a positron emission tomo-
graphic (PET) scan, the pulmonary nodule had mild
fluorodeoxyglucose (FDG) uptake that was indicative of
metabolic activity resembling a low-grade neoplasm. The
lesion was biopsied, and the result of immunohistochemi-
cal staining was negative for thyroid transcription factor-1
but positive for p63 and p40, correlating with squamous
cell carcinoma. An area within the patient’s right suprapu-
bic ramus also demonstrated abnormal FDG uptake on
the PET scan, but subsequent bone marrow biopsy of that
region revealed no evidence of metastatic cancer. On the
basis of these findings, his lung carcinoma was clinically
staged as T1M0N0.
Surgical resection of the LLL was recommended on
multiple occasions, but it was refused by the patient. He
refused additional workup or treatment and reported no
change in lifestyle. Three months later, in July 2016, a re-
peat CT scan revealed that, compared with its appearance
on the initial chest CT scan, the solitary mass had de-
creased in size to 1.6 × 0.9 × 0.9 cm (Fig. 2). The patient
underwent computed tomography a third time in August
2016, which revealed that the nodule had stabilized at its
smaller size.
Discussion
The widely accepted criteria for SR were published by
Cole and Everson in 1956 [1]. They defined SR as “the
partial or complete disappearance of a malignant tumor
in the absence of all treatment, or in the presence of
therapy which is considered inadequate to exert a sig-
nificant influence on neoplastic disease” [1]. A literature
search revealed the rare occurrence of SR in various can-
cer types, such as melanoma, renal cell carcinoma, and
neuroblastoma [3]. There are only a handful of cases in
the literature in which authors have reported SR in a
case of primary lung cancer [1, 6, 7]. Lopez-Pastorini
and colleagues [7] reported a case of presumed squa-
mous cell cancer that demonstrated SR after biopsy of a
mediastinal lymph node, but they were unable to acquire
tissue from the lung mass itself. They also summarized
older articles that show just how scarce is the number of
reported primary lung cancer SR cases; one such article
they referenced described only two reports of primary
lung cancer SR between 1951 and 2008 [7].
Investigations on the mechanisms behind tumor SR
have been inconclusive, but there are several theorized
mechanisms. These studies and case reports have postu-
lated different processes, such as immune mediation,
tumor inhibition by cytokines or growth factors, hormonal
influence, elimination of carcinogenesis, tumor necrosis,
angiogenesis inhibition, apoptosis, epigenetic mechanisms,
and induction of differentiation [2–4, 8]. A leading
hypothesis is that immunological response can be initiated
by trauma to the area, such as when a tissue biopsy is ex-
tracted [5]. In their original report, Cole and Everson
showed that 40% of their cases of SR were related to some
type pf operative trauma, and they concluded that stimu-
lation of the immune process plays a key role in SR of
cancers [1, 7]. Butterfield’s review on cancer vaccinations
mentions how surgery and tumor-ablative procedures of
Fig. 1 Thoracic computed tomographic scan taken in April 2016
Fig. 2 Repeat thoracic computed tomographic scan taken in
July 2016
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various magnitudes can be considered a sort of “cancer
vaccine” [9]. This comparison is attributed to how an abla-
tion of a mass can affect antitumor immunity by the
release of immunologically active tumor antigens that are
inevitably liberated by damaged and dying cells during the
ablation process [9]. Other authors report an “abscopal”
effect in which radiation to one mass can lead to regres-
sion in a mass that was not in the field of radiation [10].
Mechanisms for this effect are thought to be mediated by
the release of tumor antigens, “danger signals” (e.g., heat
shock proteins and high morbidity group box 1), and pro-
inflammatory cytokines [11]. This abscopal effect further
implies that insult to cancer cells may initiate an immune
response that acts more widely than the area of insult, and
efforts are underway to further understand and potentially
treat cancer with this mechanism by combining insult to
cells and immunotherapy in the form of injecting “danger
signal” proteins and proinflammatory cytokines [8, 11].
The lung cancer in our patient was essentially an inci-
dental finding based on a CT scan, and the patient reported
no significant symptoms. On the basis of current standards
of care, surgery was recommended, but the patient
declined. This aspect differs from other cases where
patients had a lung cancer workup because of their
complaints of progressive symptoms or because less sensi-
tive imaging modalities (e.g., chest X-rays) had evident
findings, indicating that the mass was potentially quite ex-
tensive/severe or metastatic. Our patient’s cancer was clin-
ically stage I. Patients in other case reports had more
advanced stages [6, 7]. Case reports involving different
stages of a tumor help further characterize SR and how it
can occur in any stage of cancer. In addition, continuing to
report patients who experience SR under any circum-
stances can potentially impact the identification of neoplas-
tic drug targets or other novel treatments of cancer. Our
patient’s case reinforces the need to further understand the
mechanisms of tumor regression and the potential for
treatment modalities that may significantly reduce the
morbidity and mortality of cancer.
Conclusions
The case of our patient meets the SR criteria discussed
in this report. The workup of the nodule revealed squa-
mous cell carcinoma of the lung in a very early stage.
Surgical resection is the standard of care and was rec-
ommended to the patient multiple times, but he de-
clined. It is inadvisable to recommend watchful waiting
in a case such as this one, but our patient’s refusal of
surgery allowed for the opportunity to follow this tumor
after biopsy. Repeat imaging 3 months after biopsy with
no further treatment revealed shrinkage of the mass.
During this period, the patient also denied any changes in
his daily medications or lifestyle. Because the tumor re-
gression became evident after the tissue was biopsied, the
patient’s immune response to the surgical procedure
seems to be a plausible factor in the occurrence of SR in
his primary lung tumor. Our patient with a tumor that
would typically be resected but was followed with imaging
after biopsy demonstrates the potential for regression fol-
lowing insult or damage to a tumor, and this case report
adds to the growing body of knowledge that implies the
possibility of effective and potentially novel
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